Phillips Medisize to present strategies for scaling complex in vitro diagnostic builds at ADLM 2026
Discover how structured collaboration with a contract development and manufacturing organization (CDMO) supports better early engineering decisions
29 Jul 2026
Phillips Medisize, a Molex company, will present strategies for scaling complex IVD builds through structured CDMO collaboration at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting.
The lecture series spotlight, titled ‘Designing for Scale through CDMO Collaboration: Lessons from Complex IVD Builds,’ will take place on Tuesday, July 28 at 10:00 PDT in Exhibit Hall Theater 2, and will focus on how IVD innovators can move from early-stage concepts to high-volume manufacturing while managing manufacturing complexity and capital risk.
Addressing IVD manufacturing complexity and capital risk
As IVD technologies advance, diagnostic companies are facing increasing complexity when scaling up manufacturing of sophisticated devices. Higher levels of automation demand that physical devices are engineered for reliable mass production, which can introduce both operational and capital risk.
IVD innovators are under pressure to design for manufacturing scalability from the earliest concept stages. Phillips Medisize has applied this approach while helping customers scale diagnostic platforms from early prototypes to more than 10x production growth, demonstrating how early engineering decisions can influence long-term commercial success.
Structured CDMO collaboration for scalable IVD platforms
During the ADLM 2026 lecture series spotlight, Phillips Medisize experts will explore how structured collaboration with a contract development and manufacturing organization (CDMO) can influence IVD project outcomes. The session will outline a practical blueprint for transitioning from early-stage concepts to high-volume manufacturing, focusing on how integrated teams can anticipate and mitigate manufacturing automation constraints.
The session will be led by Pradnya Parulekar, MPP, MBA, M.S. Finance, Associate Director of Business Development at Phillips Medisize. Drawing on lessons learned from scaling a diagnostic platform from early prototype to more than 10x production growth, Parulekar will share how a structured CDMO partnership can support better early engineering choices and de-risk the path to commercial scale.
Expert insight on designing IVD devices for scale
“Scaling up a complex diagnostic device is never a straightforward path,” said Parulekar. “Success requires an integrated approach that foresees and proactively mitigates manufacturing automation constraints. Our session at ADLM will give attendees a highly practical look at how structured CDMO collaboration can drive better early engineering choices to secure a predictable path to commercial scale.”
The presentation will be particularly relevant for IVD innovators, R&D leaders, operations teams and business development professionals seeking to understand how to align design, engineering and manufacturing strategies for scalable diagnostic platforms.
Visitors can also meet the Phillips Medisize team and learn more about its IVD, pharmaceutical drug delivery and medtech manufacturing capabilities at booth 1376.
Follow SelectScience throughout ADLM 2026 for exclusive interviews, daily round-up articles, Scientists' Choice Awards® coverage, and the latest news from the exhibition floor.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Tags
Frequently asked questions
Show frequently asked questions
What IVD manufacturing challenges will Phillips Medisize address at the ADLM 2026 Annual Meeting?
Phillips Medisize will address the growing complexity of scaling sophisticated in vitro diagnostic (IVD) devices, including higher automation requirements, operational risk and capital risk. The session will show how designing for manufacturing scalability from the earliest concept stages helps IVD innovators move from early prototypes to high-volume production while managing automation constraints and supporting long-term commercial success.
How does structured CDMO collaboration help scale complex IVD platforms?
During the ADLM 2026 lecture series spotlight, Phillips Medisize experts will explain how structured collaboration with a contract development and manufacturing organization (CDMO) supports better early engineering decisions. By using integrated teams and a practical blueprint for transitioning from early-stage concepts to high-volume manufacturing, CDMO partnerships help anticipate and mitigate manufacturing automation constraints and de-risk the path to commercial scale.
Who is leading the Phillips Medisize session at ADLM 2026 and who should attend?
The session, titled “Designing for Scale through CDMO Collaboration: Lessons from Complex IVD Builds,” will be led by Pradnya Parulekar, MPP, MBA, M.S. Finance, Associate Director of Business Development at Phillips Medisize. It is particularly relevant for IVD innovators, R&D leaders, operations teams and business development professionals seeking to align design, engineering and manufacturing strategies for scalable diagnostic platforms.